Appraisal consultation document
Closed for comments This consultation ended on at Request commenting lead permission
2 Information about rimegepant
Marketing authorisation indication
2.1 Rimegepant (Vydura, Pfizer) is indicated for the 'acute treatment of migraine with or without aura in adults' and the 'preventative treatment of episodic migraine in adults who have at least 4 migraine attacks per month'.
Dosage in the marketing authorisation
2.2 The dosage schedule is available in the summary of product characteristics for rimegepant.
Price
2.3 The price of rimegepant is £40.00 per 2 pack of 75 mg tablets (excluding VAT; BNF online accessed January 2023).
How are you taking part in this consultation?
You will not be able to change how you comment later.
You must be signed in to answer questions